Determinants of Use of Biotherapeutics in sub-Saharan Africa

被引:8
|
作者
Shah, Rajiv [1 ]
Dey, Dzifa [2 ]
Pietzonka, Thomas [3 ]
Obeng, Paul [4 ]
Ashiru, Bisola [5 ]
Schiestl, Martin [6 ]
Cavey, Andrew [5 ]
Nkansah, Edwin [7 ]
Radiere, Guerric [8 ]
Spector, Jonathan [9 ]
Scott, Christiaan [10 ,11 ]
机构
[1] Novartis, Global Hlth & Corp Responsibil, Basel, Switzerland
[2] Univ Ghana, Korle Bu Teaching Hosp, Dept Med & Therapeut, Rheumatol Unit,Med Sch, Accra, Ghana
[3] Novartis Inst BioMed Res, Basel, Switzerland
[4] Komfo Anokye Teaching Hosp, Dept Haematol Oncol & Paediat Clin Pharm, Kumasi, Ghana
[5] Novartis, Global Drug Dev, Basel, Switzerland
[6] Novartis, Sandoz, Langkampfen, Austria
[7] Food & Drugs Author FDA, Biol Prod Dept, Accra, Ghana
[8] Novartis, Sandoz, Holzkirchen, Germany
[9] Novartis Inst Trop Dis, Cambridge, MA 02139 USA
[10] Univ Cape Town, Dept Paediat Rheumatol, Cape Town, South Africa
[11] Red Cross War Mem Childrens Hosp, Cape Town, South Africa
关键词
HEALTH LITERACY; STRATEGIES; DISEASE; CHALLENGES; MECHANISMS;
D O I
10.1016/j.tips.2020.11.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Biologic drugs are reshaping clinical practice in various disciplines, even while access to them is imbalanced across global settings. In sub-Saharan Africa, biotherapeutics have potential roles to play in the treatment of a range of conditions that include infectious and noncommunicable diseases (NCDs). However, the literature is scarce on guidance for addressing local access challenges, including technical, regulatory, affordability, and other healthcare delivery aspects. This article aims to assess fundamental determinants of use of biologic medicines in sub-Saharan Africa. The purpose is to inform strategic actions of scientists, physicians, policymakers, and other stakeholders that are working to improve access to innovative therapies in low resource parts of the world.
引用
收藏
页码:75 / 84
页数:10
相关论文
共 50 条